Cerebrolysin (Brain-Derived Peptide Cocktail)
Overview
Cerebrolysin is not a single molecule but a standardised mixture of low-molecular-weight peptides and free amino acids produced by enzymatic breakdown of purified porcine brain protein. The peptide fraction (≤ ~10,000 Da) is studied for neurotrophic-factor-like activity — mimicking factors such as BDNF, GDNF and CNTF — in neurodegeneration and CNS-injury research. It is supplied as a sterile solution and is a research material.
Composition Profile
Because Cerebrolysin is a biologically-derived mixture, it is described by composition rather than a single formula.
| Property | Value |
|---|---|
| CAS number | N/A (biologically-derived mixture) |
| Class | Neurotrophic peptide cocktail |
| Composition | ≈ 80% low-MW peptides (≤ 10,000 Da), ≈ 20% free amino acids |
| Molecular-weight range | ≈ 120–10,000 Da (mostly 500–3,000 Da) |
| Source | Standardised porcine brain protein hydrolysate |
| Form | Sterile isotonic solution (ampoules) |
- Class
- Neurotrophic peptide cocktail
- Type
- Standardised mixture (not a single molecule)
- Research status
- Clinical (multiple trials for CNS indications)
- Study routes
- Intravenous (slow infusion), IM
- Key feature
- Neurotrophic-factor-like activity
Mechanism of Action
Cerebrolysin’s peptide fraction is studied for reproducing the actions of endogenous neurotrophic factors, supporting neuronal survival, synaptic plasticity and repair. Because it is a mixture, its activity is attributed to several peptide components acting on overlapping neurotrophic pathways rather than to one defined target.
| Component | Detail |
|---|---|
| Neurotrophic mimicry | BDNF-, GDNF-, CNTF- and NT-3-like activity |
| Neuroprotection | Anti-apoptotic and antioxidant effects in models |
| Synaptic plasticity | Support for synapse formation and maintenance |
| Neurogenesis | Studied for promoting neural repair |
| Amyloid research | Explored in neurodegeneration models |
Pharmacology
| Parameter | Value |
|---|---|
| Half-life (t½) | ≈ 4–6 h (mixture) |
| Route of administration | Intravenous (slow infusion), intramuscular |
| Protein content | ≈ 50 mg peptide fraction per mL (typical preparation) |
| Metabolism | Proteolytic degradation of peptide components |
| Elimination | Renal (peptide fragments and amino acids) |
Research Evidence
Cerebrolysin has a substantial clinical literature across CNS indications. Representative research areas are named below; specific numerical outcomes are not restated here as claims.
| Research area | Focus | Reference |
|---|---|---|
| Ischemic-stroke recovery | Neurological and functional outcomes | Cerebrolysin clinical literature |
| Alzheimer’s / dementia | Cognitive endpoints | Cerebrolysin clinical literature |
| Traumatic brain injury | Recovery and neuroprotection | Cerebrolysin clinical literature |
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
| Reported direction / finding | Context | Reference |
|---|---|---|
| Improved outcomes in ischemic-stroke research | clinical trials | Cerebrolysin literature |
| Cognitive endpoints in dementia research | clinical trials | Cerebrolysin literature |
| Neurotrophic-factor-like neuroprotection | preclinical models | Cerebrolysin literature |
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
Handling Reference
Handling parameters for laboratory research. Not dosing guidance for human use.
| Parameter | Reference value |
|---|---|
| Research range (literature) | ≈ 5–20 mL per administration, in study protocols |
| Form | Pre-mixed sterile solution (no reconstitution) |
| Route | Intravenous (slow infusion) or intramuscular |
| Storage | 15–25°C, sealed, protected from light |
| Do not use | If the solution is discolored or contains particulates |
Safety Profile
Published research observations, provided for reference only. This material is not for human or veterinary use.
| Category | Published observations |
|---|---|
| Tolerability | Generally well tolerated in reported studies |
| Infusion-related | Rapid infusion may cause transient warmth / dizziness |
| Origin note | Porcine-derived biological product |
| Status | For research use only; not for human or veterinary application |
Physicochemical Properties
| Property | Value |
|---|---|
| Physical state | Sterile, clear aqueous solution |
| pH | ≈ 6.5–7.0 |
| Tonicity | Isotonic |
| Composition | Peptides ≤ 10,000 Da + free amino acids |
| Storage | Room temperature (15–25°C), protected from light |
Production Process
Cerebrolysin is manufactured by standardised enzymatic hydrolysis of purified porcine brain protein, followed by filtration and standardisation of the low-molecular-weight peptide fraction — a biological-processing route, not chemical synthesis.
- Purified porcine brain protein as starting material
- Controlled enzymatic (proteolytic) hydrolysis
- Filtration to the low-molecular-weight fraction (≤ ~10,000 Da)
- Standardisation, sterile filtration and filling into ampoules
Analytical Methods
Because Cerebrolysin is a standardised biological mixture rather than a single molecule, quality control is about batch-to-batch consistency — the peptide fingerprint, molecular-weight distribution and total peptide/amino-acid content — plus the usual checks for an injectable solution.
| Method | Purpose | Typical result |
|---|---|---|
| HPLC peptide fingerprinting | Batch consistency | Reproducible peptide profile |
| Size-exclusion chromatography (SEC) | Molecular-weight distribution | ≤ ~10,000 Da fraction (mostly 500–3,000) |
| Amino-acid analysis | Free-amino-acid content | Within specification (~20%) |
| Total protein / peptide assay | Concentration | ≈ 50 mg peptide/mL (typical) |
| LAL assay | Endotoxin | Within limit for an injectable |
| pH | Solution pH | ≈ 6.5–7.0 |
| Osmolality | Isotonicity | Isotonic |
| Sterility | Microbial safety | Sterile |
- No single-compound identity is defined; consistency is judged against a reference fingerprint and the MW-distribution profile.
Stability Data
| Condition | Duration | Result |
|---|---|---|
| Sealed ampoule, 15–25°C, dark | Per labelled shelf-life | Stable |
| Sealed ampoule, brief 2–8°C | Short-term | Acceptable; do not freeze |
| After opening | Use promptly | Single use — do not store opened ampoules |
| Diluted in infusion fluid | Use within hours | Prepare immediately before use |
| Light exposure | — | Protect from light |
| Freezing | — | Do NOT freeze (damages the preparation) |
- Keep ampoules sealed, at room temperature (15–25°C) and protected from light; never freeze.
- It is a pre-mixed solution — no reconstitution; if diluted for infusion, prepare immediately before use.
Selected References
- Cerebrolysin clinical literature in ischemic stroke, dementia and traumatic brain injury.
- Reviews of brain-derived peptide preparations and neurotrophic mimetics.
Quality & Supply
- Standardised peptide-fraction preparation with batch documentation
- Consistency verified by peptide fingerprint and MW-distribution analysis
- Research quantities with worldwide delivery
- Supplied as sealed sterile ampoules
Need Cerebrolysin — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
